$4.33
0.133.21%
Last update: Nov 11, 11:09 AM
Nuvation Bio Inc
NUVBNYSE
Nuvation Bio fell 15.7% from $4.98 to $4.20, behind the S&P 500's +9.8%. Its worst day was Mar 3 (−25.3%), and its low came Mar 30 at $4.05.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Nuvation Bio shares rose 49.0%, while the S&P 500 rose 0.4%.
+49.0%, the year's best day, on 59M shares, the year's heaviest volume · S&P 500 +0.4%
Story events cover the past 12 months · Times ET
Nuvation Bio closed at its highest level of the year, 91.6% above where the year started.
+1.1% · S&P 500 +0.6%
Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of
−19.7% · S&P 500 +0.2%
EPS of $-0.11 missed the $-0.07 estimate on $41.9M revenue (est. $33.5M).
−25.3%, the year's worst day · S&P 500 −0.9%
Nuvation Bio closed at its lowest level of the year, 18.7% below where the year started.
−4.7% · S&P 500 −0.3%
EPS of $0.01 missed the $0.06 estimate on $83.2M revenue (est. $68.4M).
+9.5% · S&P 500 +0.8%
EPS of $-0.18 missed the $-0.13 estimate on $31.7M revenue (est. $27.5M).
−4.1% · S&P 500 −0.2%
EPS of $-0.12 missed the $-0.10 estimate on $45.0M revenue (est. $34.3M).
−11.4% · S&P 500 −4.4%
Where it ended: a close of $4.20 on Nov 10, 2026. Up next: Q4 2026 earnings on Mar 1, 2027 (EPS est. $-0.10, revenue est. $43.0M).
Nothing in the past 12 months.
All NUVB dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for NUVB and SPY from Benzinga historical bars. Not investment advice.
